Withdrawn before it began
Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy
NCT03528057 · Northwestern University · Updated 5 July 2019
- What is being tested
- Hemostat
- For
- Robotic-Assisted Laparoscopic Partial Nephrectomy; Hemostatic Agents; Renal Malignant Tumor
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 89 years. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 18 April 2018, ends June 2020. Registered 17 May 2018.
- Results
- None posted yet.
In the researchers' words
The aim of this study is to evaluate whether Hemostatic Agents (HA) make a significant clinical difference in patient outcomes when used for Robotic-Assisted Laparoscopic Partial Nephrectomy (RALPN). The result of this trial will determine whether HAs are necessary for use during RALPN or if they can be omitted from the surgical tools available during this procedure. This study has a direct clinical implication on a patient's outcomes following RALPN, specifically whether patients will have better, worse, or unchanged outcomes with RALPN if HAs are used.
Sites
- Northwestern Memorial HospitalChicago, Illinois, United States